Akums Drugs and Pharmaceuticals Limited

NSEI:AKUMS Stock Report

Market Cap: ₹91.4b

Akums Drugs and Pharmaceuticals Past Earnings Performance

Past criteria checks 3/6

Akums Drugs and Pharmaceuticals has been growing earnings at an average annual rate of 36.2%, while the Life Sciences industry saw earnings growing at 25.2% annually. Revenues have been growing at an average rate of 2.4% per year. Akums Drugs and Pharmaceuticals's return on equity is 10%, and it has net margins of 6.8%.

Key information

36.2%

Earnings growth rate

36.1%

EPS growth rate

Life Sciences Industry Growth11.2%
Revenue growth rate2.4%
Return on equity10.0%
Net Margin6.8%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Akums Drugs and Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NSEI:AKUMS Revenue, expenses and earnings (INR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2440,8272,7787,2770
30 Jun 2442,3092,4447,1150
31 Mar 2441,817-406,9180
31 Dec 2340,846-6716,7370
30 Sep 2339,875-1,3026,5550
30 Jun 2337,158-1,2776,2580
31 Mar 2336,5729496,2910
31 Mar 2236,752-2,5255,3990
31 Mar 2127,2621,2274,5410

Quality Earnings: AKUMS has high quality earnings.

Growing Profit Margin: AKUMS became profitable in the past.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: AKUMS's earnings have grown significantly by 36.2% per year over the past 5 years.

Accelerating Growth: AKUMS has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: AKUMS has become profitable in the last year, making it difficult to compare its past year earnings growth to the Life Sciences industry (37.9%).


Return on Equity

High ROE: AKUMS's Return on Equity (10%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies